Sherman D. Basinger

Array ( [id] => 20497632 [patent_doc_number] => 20260027089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-29 [patent_title] => MrgprX2 Antagonists for the Treatment of Inflammatory Disorders [patent_app_type] => utility [patent_app_number] => 19/349768 [patent_app_country] => US [patent_app_date] => 2025-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19349768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20377639 [patent_doc_number] => 20250360132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-27 [patent_title] => METHODS OF ADMINISTERING MYOSIN INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/287195 [patent_app_country] => US [patent_app_date] => 2025-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40417 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19287195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20377619 [patent_doc_number] => 20250360112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-27 [patent_title] => 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 19/038137 [patent_app_country] => US [patent_app_date] => 2025-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19038137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20007343 [patent_doc_number] => 20250145565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/985720 [patent_app_country] => US [patent_app_date] => 2024-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18985720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19860686 [patent_doc_number] => 20250099472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS [patent_app_type] => utility [patent_app_number] => 18/973200 [patent_app_country] => US [patent_app_date] => 2024-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18973200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20432512 [patent_doc_number] => 12502380 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => MrgprX2 antagonists for the treatment of inflammatory disorders [patent_app_type] => utility [patent_app_number] => 18/923566 [patent_app_country] => US [patent_app_date] => 2024-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29774 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18923566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743933 [patent_doc_number] => 20250032498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS [patent_app_type] => utility [patent_app_number] => 18/912939 [patent_app_country] => US [patent_app_date] => 2024-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18912939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19845158 [patent_doc_number] => 20250090509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/884941 [patent_app_country] => US [patent_app_date] => 2024-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18884941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800450 [patent_doc_number] => 20250066375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/812527 [patent_app_country] => US [patent_app_date] => 2024-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 369 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18812527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20443935 [patent_doc_number] => 20260000649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-01 [patent_title] => TOPICAL FORMULATIONS FOR INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/759222 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18759222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430819 [patent_doc_number] => 20240299317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization [patent_app_type] => utility [patent_app_number] => 18/663524 [patent_app_country] => US [patent_app_date] => 2024-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8927 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18663524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20505038 [patent_doc_number] => 12539300 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-03 [patent_title] => Method of treating seizures and epilepsy using liquid pharmaceutical composition for oral dosage of vigabatrin [patent_app_type] => utility [patent_app_number] => 18/661306 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4013 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492588 [patent_doc_number] => 12534450 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Methods and compositions for targeting PD-L1 [patent_app_type] => utility [patent_app_number] => 18/658848 [patent_app_country] => US [patent_app_date] => 2024-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27446 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18658848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417270 [patent_doc_number] => 20240293393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => RAMIPRIL SOLUTION FOR ORAL DOSAGE [patent_app_type] => utility [patent_app_number] => 18/652993 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18652993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19387864 [patent_doc_number] => 20240277734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => COMPOSITION COMPRISING LIPOIC ACID AND VITAMIN D FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES AND PERIPHERAL NEUROPATHIES [patent_app_type] => utility [patent_app_number] => 18/646365 [patent_app_country] => US [patent_app_date] => 2024-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12748 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18646365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379252 [patent_doc_number] => 20240269122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => NASAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/638204 [patent_app_country] => US [patent_app_date] => 2024-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401229 [patent_doc_number] => 12491189 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => OTIC formulations, methods and devices [patent_app_type] => utility [patent_app_number] => 18/638340 [patent_app_country] => US [patent_app_date] => 2024-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1779 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18638340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360791 [patent_doc_number] => 20240262825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => PAIN TREATING COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/602482 [patent_app_country] => US [patent_app_date] => 2024-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18602482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19263511 [patent_doc_number] => 20240207208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => Treatments for Diabetes Mellitus and Obesity [patent_app_type] => utility [patent_app_number] => 18/599902 [patent_app_country] => US [patent_app_date] => 2024-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18599902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332482 [patent_doc_number] => 20240246912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => CRYSTALLINE SALTS OF PSILOCIN [patent_app_type] => utility [patent_app_number] => 18/591925 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18591925 [rel_patent_id] =>[rel_patent_doc_number] =>)